A new series of studies were unveiled, highlighting the prognostic value of Brainomix lung imaging biomarkers in patients with fibrotic lung disease.
With these latest studies, the firmly established European market leader in stroke AI imaging adds to its growing body of evidence. The latest research reflects the company's extensive academic collaborations and its growing Life Science partnerships.
The largest real-world evaluation of stroke AI imaging, involving more than 80,000 patients at 26 sites over a 3-year period, showed Brainomix 360 Stroke was associated with an additional 50% increase in the number of patients receiving mechanical thrombectomy, while also improving the speed of treatment by 49 minutes.
Brainomix and AstraZeneca partnered to analyze the Phase 2 tralokinumab clinical trial data of Idiopathic Pulmonary Fibrosis (IPF) patients, leveraging Brainomix's AI-powered e-Lung software and biomarkers to uncover novel insights. Published data shows e-Lung could play a role in stratifying patients in clinical trials most at risk of decline, outperforming current standard measures.
Study conducted at UCL Hospital in London adds to the growing body of real-world evidence showcasing the clinical value that e-ASPECTS can deliver to stroke teams.
Study demonstrates the value of our unique e-Lung biomarkers to accurately predict IPF patients at risk of future lung function decline, a prognostic capability which can benefit future clinical trials.
A newly published study in Frontiers demonstrates the impact of the Brainomix 360 Stroke platform, trebling the number of stroke patients achieving a better outcome.
Results will enable stroke networks to make more confident treatment decisions in both specialist and non-specialist stroke hospitals
e-Stroke Suite increased thrombolysis and thrombectomy treatment rates for stroke patients
New study shows Brainomix’s unique AI-driven software gives doctors reliable information to treat stroke patients from universally available imaging systems
First trial to demonstrate efficacy of thrombectomy in developing world healthcare system
New study shows Brainomix e-CTA provides similar measures to experts and improves inter-rater reliability
Guidelines reinforce the importance of imaging in determining patient eligibility
Ischemic injury on e-ASPECTS, but not RAPID software, predicted good clinical outcome at 3 months after stroke
Study suggests it may be reasonable to select patients for thrombectomy in centres without access to advanced imaging using the e-ASPECTS tool in combination with clinical criteria
New publication in Stroke journal with 1,500 patients from the ENCHANTED trial database
The only mechanical thrombectomy trial in a developing country is currently taking place in Brazil
A new study shows e-ASPECTS correlates with and is a predictor of outcome
Results show e-ASPECTS is on average statistically non-inferior to expert neuroradiologists
Study illustrates the potential benefits of e-ASPECTS when integrated within Mobile Stroke Units
Study shows e-ASPECTS performs as well as stroke experts when assessing brain CT scans of stroke patients